{
    "hands_on_practices": [
        {
            "introduction": "Distinguishing between different forms of immune-complex glomerulonephritis is a cornerstone of pediatric nephrology. This practice problem challenges you to differentiate Henoch–Schönlein purpura nephritis (HSPN) from lupus nephritis by applying fundamental immunological principles. By analyzing serologic markers, complement pathway activation, and immunofluorescence patterns, you will reinforce your understanding of how distinct pathogenic mechanisms produce unique and identifiable clinical profiles .",
            "id": "5151928",
            "problem": "A pediatric nephrology fellow is evaluating two school-aged children with acute glomerulonephritis characterized by hematuria and subnephrotic proteinuria. The goal is to distinguish lupus nephritis from Henoch–Schönlein purpura nephritis using fundamental immunology of complement activation and immune complex deposition, rather than pattern recall. Consider the following blinded renal–serologic profiles, each consisting of serum markers, complement levels, and renal immunofluorescence (IF, Immunofluorescence):\n\nProfile $1$:\n- Serum: Antinuclear antibody (ANA) strongly positive; anti–double-stranded DNA (anti-dsDNA) positive.\n- Complement: Low $C3$ and low $C4$.\n- Kidney IF: Granular capillary loop and mesangial deposits with simultaneous staining for IgG, IgA, IgM, $C3$, and $C1q$.\n\nProfile $2$:\n- Serum: ANA negative; elevated serum immunoglobulin A (IgA).\n- Complement: $C3$ and $C4$ within reference intervals.\n- Kidney IF: Mesangial-dominant IgA with $C3$, minimal to absent IgG, IgM, and $C1q$.\n\nStarting from the following well-tested immunologic facts:\n- The classical complement pathway is initiated by $C1q$ binding to immune complexes containing IgG or IgM, typically leading to consumption of both $C4$ and $C3$ in active disease.\n- IgA does not efficiently activate the classical pathway via $C1q$; IgA-containing immune complexes can engage the alternative and lectin pathways, which do not require $C1q$, and therefore typically do not lower $C4$ and may leave $C3$ normal or only mildly reduced.\n\nWhich option correctly assigns the profiles to lupus nephritis versus Henoch–Schönlein purpura (IgA vasculitis) nephritis and correctly explains the observed complement and IF patterns in mechanistic terms?\n\nA. Profile $1$ is Henoch–Schönlein purpura nephritis and Profile $2$ is lupus nephritis; because IgA immune complexes robustly activate the classical pathway via $C1q$, leading to low $C4$, whereas IgG complexes do not consume $C4$.\n\nB. Profile $1$ is lupus nephritis and Profile $2$ is Henoch–Schönlein purpura nephritis; because IgG- and IgM-containing immune complexes activate the classical pathway and consume $C3$ and $C4$, and the “full-house” IF pattern with $C1q$ reflects classical pathway activation, whereas IgA-dominant complexes do not efficiently engage $C1q$, so complements are often normal and $C1q$ staining is minimal or absent.\n\nC. Profile $1$ is lupus nephritis and Profile $2$ is Henoch–Schönlein purpura nephritis; because both diseases are mediated by IgA-dominant immune complexes, but lupus is typically pauci-immune on IF, explaining low complement levels.\n\nD. Profile $1$ is Henoch–Schönlein purpura nephritis and Profile $2$ is lupus nephritis; because the “full-house” IF pattern is characteristic of IgA vasculitis, whereas lupus nephritis usually shows isolated IgG staining without $C1q$.",
            "solution": "The problem statement will first be validated for scientific soundness, clarity, and completeness.\n\n**Step 1: Extract Givens**\n- **Condition:** Two pediatric patients with acute glomerulonephritis (hematuria, subnephrotic proteinuria).\n- **Diseases to Differentiate:** Lupus nephritis versus Henoch-Schönlein purpura (HSP) nephritis (IgA vasculitis).\n- **Profile $1$ Data:**\n    - Serum: Antinuclear antibody (ANA) strongly positive; anti-double-stranded DNA (anti-dsDNA) positive.\n    - Complement: Low $C3$ and low $C4$.\n    - Kidney Immunofluorescence (IF): Granular capillary loop and mesangial deposits with staining for IgG, IgA, IgM, $C3$, and $C1q$.\n- **Profile $2$ Data:**\n    - Serum: ANA negative; elevated serum immunoglobulin A (IgA).\n    - Complement: $C3$ and $C4$ within reference intervals.\n    - Kidney IF: Mesangial-dominant IgA with $C3$; minimal to absent IgG, IgM, and $C1q$.\n- **Provided Immunologic Principles:**\n    1. The classical complement pathway is initiated by $C1q$ binding to immune complexes containing IgG or IgM, consuming both $C4$ and $C3$.\n    2. IgA-containing immune complexes do not efficiently activate the classical pathway via $C1q$. They can activate the alternative and lectin pathways, which do not require $C1q$, characteristically sparing $C4$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is well-posed and scientifically grounded.\n- **Scientific Soundness:** The clinical and laboratory profiles presented for the two conditions are classic, textbook descriptions of lupus nephritis and HSP nephritis. Lupus nephritis is an immune-complex glomerulonephritis, prototypically involving autoantibodies like ANA and anti-dsDNA, leading to the formation of immune complexes containing IgG and IgM. These complexes deposit in the kidney and activate the classical complement pathway, resulting in a \"full-house\" immunofluorescence pattern (IgG, IgA, IgM, $C3$, $C1q$) and consumption of complement components ($C3$ and $C4$). HSP nephritis (IgA vasculitis) is characterized by the deposition of IgA-containing immune complexes, which primarily activate the alternative and lectin pathways, thus sparing the early classical pathway components ($C1q$, $C4$) and resulting in IgA-dominant staining on IF with normal serum complement levels. The provided immunologic principles are fundamental and correct tenets of immunology.\n- **Clarity and Completeness:** The problem provides two distinct, internally consistent profiles and a clear question. All necessary information to distinguish the two conditions based on the provided principles is present. There are no contradictions, ambiguities, or missing data.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. I will proceed with the solution derivation and option analysis.\n\n**Derivation of Solution**\n\nThe task is to assign each profile to either lupus nephritis or HSP nephritis by applying the provided immunologic principles.\n\n**Analysis of Profile $1$:**\nThe patient has strongly positive ANA and anti-dsDNA, which are highly specific autoantibodies for systemic lupus erythematosus (SLE). The associated kidney disease is lupus nephritis. The serology is therefore highly suggestive of lupus nephritis. The complement profile shows low $C3$ and low $C4$. As per the provided principles, consumption of both $C4$ and $C3$ is characteristic of classical complement pathway activation. This pathway is initiated when $C1q$ binds to immune complexes containing IgG or IgM. The immunofluorescence (IF) findings confirm this mechanism: there are deposits of IgG and IgM, which are the requisite activators, and crucially, there is also deposition of $C1q$, the initiating protein of the classical pathway. The deposition of $C3$ is the expected downstream consequence. The combination of IgG, IgA, IgM, $C3$, and $C1q$ is known as a \"full-house\" pattern, which is pathognomonic for lupus nephritis. Therefore, Profile $1$ is a classic presentation of lupus nephritis, where immune complexes containing IgG and IgM trigger the classical complement cascade.\n\n**Analysis of Profile $2$:**\nThe patient is ANA negative, making SLE unlikely. The serum shows elevated IgA, a common finding in IgA vasculitis (HSP). The complement levels ($C3$ and $C4$) are normal. As per the provided principles, normal $C4$ suggests the classical pathway is not activated. This is consistent with a disease process mediated by IgA, which does not efficiently activate the classical pathway. The IF findings are definitive: deposits are dominated by IgA. Consistent with the lack of classical pathway activation, staining for $C1q$ is minimal to absent. The presence of $C3$ deposition without $C1q$ or consumption of $C4$ indicates activation of the alternative or lectin pathway, which is the known pathophysiology of IgA-mediated nephritis. Therefore, Profile $2$ is a classic presentation of HSP nephritis.\n\n**Conclusion:**\nProfile $1$ is lupus nephritis.\nProfile $2$ is Henoch-Schönlein purpura nephritis.\n\n**Option-by-Option Analysis**\n\n**A. Profile $1$ is Henoch–Schönlein purpura nephritis and Profile $2$ is lupus nephritis; because IgA immune complexes robustly activate the classical pathway via $C1q$, leading to low $C4$, whereas IgG complexes do not consume $C4$.**\nThis option has the disease assignments reversed. The reasoning provided is also factually incorrect and directly contradicts the immunological principles given in the problem statement. IgA does *not* robustly activate the classical pathway, and IgG immune complexes *do* activate it, consuming $C4$.\n**Verdict: Incorrect.**\n\n**B. Profile $1$ is lupus nephritis and Profile $2$ is Henoch–Schönlein purpura nephritis; because IgG- and IgM-containing immune complexes activate the classical pathway and consume $C3$ and $C4$, and the “full-house” IF pattern with $C1q$ reflects classical pathway activation, whereas IgA-dominant complexes do not efficiently engage $C1q$, so complements are often normal and $C1q$ staining is minimal or absent.**\nThis option correctly assigns Profile $1$ to lupus nephritis and Profile $2$ to HSP nephritis. The reasoning provided is entirely correct and perfectly aligns with the derivation based on the provided principles. It correctly links the findings in Profile $1$ (IgG/IgM, low $C3$/$C4$, $C1q$ deposition) to classical pathway activation. It also correctly links the findings in Profile $2$ (IgA-dominant, normal complements, no $C1q$) to a pathway that bypasses the classical activation sequence.\n**Verdict: Correct.**\n\n**C. Profile $1$ is lupus nephritis and Profile $2$ is Henoch–Schönlein purpura nephritis; because both diseases are mediated by IgA-dominant immune complexes, but lupus is typically pauci-immune on IF, explaining low complement levels.**\nThis option correctly assigns the diseases but the reasoning is fundamentally flawed. Lupus nephritis is not IgA-dominant; it is characterized by a \"full-house\" pattern. Furthermore, lupus nephritis is the archetypal immune-complex disease, not \"pauci-immune\" (which means few or no immune deposits). A pauci-immune condition would not be expected to cause low systemic complement levels, as there would be no large-scale immune complex formation to consume complement.\n**Verdict: Incorrect.**\n\n**D. Profile $1$ is Henoch–Schönlein purpura nephritis and Profile $2$ is lupus nephritis; because the “full-house” IF pattern is characteristic of IgA vasculitis, whereas lupus nephritis usually shows isolated IgG staining without $C1q$.**\nThis option has the disease assignments reversed. The reasoning is also factually incorrect. The \"full-house\" IF pattern is the hallmark of lupus nephritis, not IgA vasculitis. Conversely, lupus nephritis does not typically show isolated IgG staining without $C1q$; the presence of $C1q$ is a key feature reflecting classical pathway activation.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Accurately assessing kidney function is critical for managing Henoch–Schönlein purpura nephritis. This exercise provides practical experience in calculating the estimated glomerular filtration rate ($eGFR$) for a pediatric patient using the bedside Schwartz equation, a standard clinical tool. By applying this formula, you will translate routine laboratory and anthropometric data into a quantitative measure of renal function, a skill essential for staging kidney disease and monitoring its progression .",
            "id": "5151961",
            "problem": "A child with Henoch–Schönlein purpura nephritis presents with edema and microscopic hematuria. The child is aged $9$ years, has a measured standing height of $132$ $\\text{cm}$, and a same-day serum creatinine measured by an isotope dilution mass spectrometry (IDMS)-traceable enzymatic assay of $1.05$ $\\text{mg/dL}$. Starting from the definition of glomerular filtration rate as a clearance (volume per unit time) and the empiric observation that, in children at steady state, creatinine generation scales with linear body size, use the bedside Schwartz approach with the IDMS-standardized pediatric proportionality constant $k$ to estimate the glomerular filtration rate. Take $k = 0.413$. Round your estimated glomerular filtration rate to four significant figures and express it in $\\text{mL/min}$ per $1.73\\,\\text{m}^2$. In your reasoning, identify the Kidney Disease: Improving Global Outcomes glomerular filtration rate category that corresponds to the calculated value for this child with Henoch–Schönlein purpura nephritis. Provide only the numeric estimated glomerular filtration rate as your final answer.",
            "solution": "The problem is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\n- **Diagnosis**: Henoch–Schönlein purpura nephritis\n- **Patient Age**: $9$ years\n- **Patient Height ($L$)**: $132$ $\\text{cm}$\n- **Serum Creatinine ($P_{Cr}$)**: $1.05$ $\\text{mg/dL}$ (measured by an IDMS-traceable enzymatic assay)\n- **Proportionality Constant ($k$)**: $0.413$ (for IDMS-standardized Schwartz equation)\n- **Target Unit for GFR**: $\\text{mL/min}$ per $1.73\\,\\text{m}^2$\n- **Required Precision**: Round to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific or Factual Soundness**: The problem is scientifically grounded. It addresses the estimation of glomerular filtration rate (GFR) in a pediatric patient with a known condition (Henoch–Schönlein purpura nephritis), which commonly affects renal function. It utilizes the \"bedside\" Schwartz equation, a widely accepted and empirically derived formula for estimating GFR in children. The specified constant $k = 0.413$ is the correct, standardized value for use with isotope dilution mass spectrometry (IDMS)-traceable serum creatinine assays. The patient's height, age, and serum creatinine level are plausible for a child experiencing nephritis. The problem is free of scientific flaws.\n2.  **Non-Formalizable or Irrelevant**: The problem is directly relevant to the topic of pediatric nephrology and specifically Henoch-Schönlein purpura nephritis. It is a formal, quantitative problem.\n3.  **Incomplete or Contradictory Setup**: All necessary variables for the bedside Schwartz equation ($L$, $P_{Cr}$, and $k$) are provided. There are no contradictions.\n4.  **Unrealistic or Infeasible**: The presented clinical scenario and data are realistic.\n5.  **Ill-Posed or Poorly Structured**: The problem is well-posed, asking for a specific calculation using a clearly defined method, which will yield a unique numerical solution. The terms are standard in nephrology.\n6.  **Pseudo-Profound, Trivial, or Tautological**: The problem requires the correct application of a standard clinical estimation formula and the interpretation of the result in the context of established clinical guidelines (KDIGO). It is neither trivial nor tautological.\n7.  **Outside Scientific Verifiability**: The calculation is verifiable and based on established clinical practice.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be provided.\n\nThe glomerular filtration rate (GFR) is defined as the volume of fluid filtered from the renal glomerular capillaries into Bowman's capsule per unit time. It represents a fundamental measure of kidney function. Direct measurement of GFR is complex, so it is typically estimated using clearance principles. The clearance of a substance is the hypothetical volume of plasma from which the substance is completely removed per unit time. For a substance that is freely filtered at the glomerulus and is neither reabsorbed nor secreted by the renal tubules, its clearance is equal to the GFR.\n\nMathematically, the clearance ($C_x$) of a substance $x$ is given by:\n$$C_x = \\frac{U_x \\times V}{P_x}$$\nwhere $U_x$ is the urinary concentration of $x$, $V$ is the urine flow rate, and $P_x$ is the plasma concentration of $x$. The term $U_x \\times V$ represents the excretion rate of the substance.\n\nCreatinine is an endogenous substance used to estimate GFR. It is a metabolic product of creatine phosphate in muscle. In a steady state, the rate of creatinine generation by muscle is constant and equals its rate of excretion by the kidneys. The problem states that in children, creatinine generation is observed to be proportional to linear body size, i.e., height ($L$). Therefore:\n$$\\text{Creatinine Excretion Rate} = U_{Cr} \\times V \\propto L$$\nwhere $U_{Cr}$ is the urinary creatinine concentration.\n\nThe estimated GFR (eGFR) can be approximated by the creatinine clearance ($C_{Cr}$):\n$$eGFR \\approx C_{Cr} = \\frac{U_{Cr} \\times V}{P_{Cr}}$$\nSubstituting the proportionality for the excretion rate, we find:\n$$eGFR \\propto \\frac{L}{P_{Cr}}$$\nThis proportionality forms the basis of the empiric bedside Schwartz equation:\n$$eGFR = \\frac{k \\times L}{P_{Cr}}$$\nHere, $k$ is an empirically determined proportionality constant that accounts for the average creatinine production rate for a given population, as well as the units of measurement. The value of $k$ depends on the method used to measure serum creatinine. The problem specifies an IDMS-traceable enzymatic assay, for which the established constant is $k = 0.413$. The formula is designed such that if height ($L$) is in $\\text{cm}$ and serum creatinine ($P_{Cr}$) is in $\\text{mg/dL}$, the resulting eGFR is in the standard units of $\\text{mL/min}/1.73\\,\\text{m}^2$.\n\nThe given values are:\n- Height, $L = 132\\,\\text{cm}$\n- Serum creatinine, $P_{Cr} = 1.05\\,\\text{mg/dL}$\n- Constant, $k = 0.413$\n\nSubstituting these values into the bedside Schwartz equation:\n$$eGFR = \\frac{0.413 \\times 132}{1.05}$$\nFirst, we calculate the numerator:\n$$0.413 \\times 132 = 54.516$$\nNext, we perform the division:\n$$eGFR = \\frac{54.516}{1.05} \\approx 51.920$$\nThe problem requires rounding the result to four significant figures. Thus, the estimated glomerular filtration rate is $51.92\\,\\text{mL/min}/1.73\\,\\text{m}^2$.\n\nThe problem also asks to identify the Kidney Disease: Improving Global Outcomes (KDIGO) GFR category. The KDIGO guidelines classify chronic kidney disease based on GFR as follows:\n- Category G1: GFR $\\ge 90\\,\\text{mL/min}/1.73\\,\\text{m}^2$ (Normal or high)\n- Category G2: GFR $60-89\\,\\text{mL/min}/1.73\\,\\text{m}^2$ (Mildly decreased)\n- Category G3a: GFR $45-59\\,\\text{mL/min}/1.73\\,\\text{m}^2$ (Mildly to moderately decreased)\n- Category G3b: GFR $30-44\\,\\text{mL/min}/1.73\\,\\text{m}^2$ (Moderately to severely decreased)\n- Category G4: GFR $15-29\\,\\text{mL/min}/1.73\\,\\text{m}^2$ (Severely decreased)\n- Category G5: GFR $< 15\\,\\text{mL/min}/1.73\\,\\text{m}^2$ (Kidney failure)\n\nThe calculated eGFR of $51.92\\,\\text{mL/min}/1.73\\,\\text{m}^2$ falls within the range for Category G3a, indicating mildly to moderately decreased kidney function. This finding is consistent with the diagnosis of Henoch-Schönlein purpura nephritis. The final answer required is the numerical value of the eGFR.",
            "answer": "$$\\boxed{51.92}$$"
        },
        {
            "introduction": "Effective management of severe Henoch–Schönlein purpura nephritis requires not only initiating appropriate therapy but also skillfully adjusting it based on the patient's response. This practice problem focuses on the therapeutic cornerstone of corticosteroids, guiding you through the calculation of an initial weight-based dose of prednisone. More importantly, it challenges you to think critically about designing a tapering schedule that is tied to objective clinical and laboratory markers of disease activity .",
            "id": "5152014",
            "problem": "A child with Immunoglobulin A (IgA) vasculitis, formerly known as Henoch-Schönlein purpura, presents with nephritis characterized by nephrotic-range proteinuria and preserved kidney function. The child weighs $30$ kg. The treatment plan is to initiate oral prednisone at $2$ mg/kg/day in a single daily dose. Calculate the initial daily prednisone dose using linear weight-based dosing derived from dose proportionality (dose equals the product of weight and the per-kilogram dose), and express your answer in mg/day. Do not include units in your final numeric answer, but interpret the result as mg/day. In addition, outline a physiologically reasoned taper plan tied to objective clinical and laboratory response for IgA vasculitis nephritis. The taper should be based on normalization or improvement in measurable endpoints such as urine protein-to-creatinine ratio, microscopic hematuria, blood pressure, and estimated glomerular filtration rate, and should reduce dose gradually to mitigate hypothalamic-pituitary-adrenal axis suppression and prevent relapse. You may assume typical pediatric practice constraints that full-dose courses are maintained until objective improvement is achieved before tapering is attempted. The only quantity you must calculate is the initial daily prednisone dose; no rounding is required beyond exact arithmetic. Express the final dose in mg/day.",
            "solution": "The fundamental base is linear weight-based dosing, which applies direct proportionality between a per-kilogram dose and a patient’s weight. If a medication is prescribed at $d$ mg/kg/day and the patient’s weight is $w$ kg, then the initial daily dose $D$ in mg/day is given by\n$$\nD = d \\times w.\n$$\nFor prednisone in pediatric IgA vasculitis nephritis (Henoch-Schönlein purpura nephritis), a common initial anti-inflammatory regimen uses $d = 2$ mg/kg/day. The child’s weight is $w = 30$ kg. Substituting into the proportionality,\n$$\nD = 2 \\,\\text{mg/kg/day} \\times 30 \\,\\text{kg} = 60 \\,\\text{mg/day}.\n$$\nNo rounding is required because the product is an exact integer.\n\nOutline of a physiologically reasoned taper plan tied to objective response:\n- Clinical goals and measurable targets: Aim for sustained reduction of inflammation and proteinuria while minimizing toxicity and hypothalamic-pituitary-adrenal axis suppression. Objective endpoints typically include:\n  - Urine protein-to-creatinine ratio (UPCR) falling from nephrotic range toward remission, with practical thresholds such as UPCR below $0.5~\\text{mg/mg}$ and ideally approaching below $0.2~\\text{mg/mg}$, sustained for at least $7$ consecutive days.\n  - Microscopic hematuria improving, for example red blood cells per high-power field trending downward and ideally below $10$ cells per high-power field on repeated urinalyses.\n  - Blood pressure (BP) at age-, sex-, and height-adjusted normal values without escalation of antihypertensive requirements.\n  - Estimated glomerular filtration rate (eGFR) at or above $90~\\text{mL/min}$ per $1.73~\\text{m}^2$, stable without a declining trend.\n- Full-dose phase: Maintain the full daily dose $60$ mg/day initially until objective improvement is demonstrated. In many pediatric protocols this full-dose phase is maintained for approximately $14$ to $28$ days, but the key principle is that the duration is response-guided rather than arbitrary.\n- Taper initiation criteria: Begin taper once there is evidence of disease control, for example:\n  - UPCR below $0.5~\\text{mg/mg}$ and decreasing on at least two measurements over $7$ to $10$ days.\n  - Microscopic hematuria improving as above.\n  - BP controlled and eGFR stable at or above $90~\\text{mL/min}$ per $1.73~\\text{m}^2$.\n  - No new edema or extrarenal flare.\n- Taper mechanics: Reduce the dose gradually to mitigate risk of clinical relapse and avoid abrupt hypothalamic-pituitary-adrenal axis withdrawal. Two equivalent approaches may be used:\n  - Fractional reductions: Decrease the current daily dose by $0.1$ to $0.2$ of the current dose per week while monitoring targets. For example, from $60$ mg/day, a $0.17$ fractional decrease moves to approximately $50$ mg/day after $7$ days of stability; further weekly decrements of $0.1$ to $0.2$ of the then-current dose follow as long as targets are maintained.\n  - Fixed-step reductions: Reduce by $5$ mg to $10$ mg per week at higher doses, then by $2.5$ mg steps at lower doses, provided the clinical and laboratory endpoints remain stable or continue to improve.\n- Guardrails and holding criteria:\n  - If UPCR rebounds above $1~\\text{mg/mg}$, hematuria worsens, edema recurs, BP rises, or eGFR declines, hold the taper and revert to the last effective dose; consider returning to the most recent higher dose that controlled disease for at least $7$ days and reassess for concomitant measures (e.g., renin-angiotensin-aldosterone system blockade).\n  - Once the dose is at physiologic equivalence ranges, taper more slowly (for example, dose reductions by $0.05$ to $0.1$ of the current dose every $1$ to $2$ weeks) to reduce the risk of hypothalamic-pituitary-adrenal axis suppression and rebound.\n- Discontinuation criteria:\n  - Sustained UPCR below $0.2~\\text{mg/mg}$, stable or resolved microscopic hematuria, controlled BP, and eGFR at or above $90~\\text{mL/min}$ per $1.73~\\text{m}^2$ for several weeks with no extrarenal flare.\n  - Consider a brief alternate-day bridge at low doses before cessation if taper intolerance is suspected.\n\nPhysiologic rationale: The initial high-dose phase dampens mesangial Immunoglobulin A–mediated inflammation and reduces glomerular permeability, lowering proteinuria. Tapering is response-guided to maintain remission while allowing hypothalamic-pituitary-adrenal axis recovery. Fractional or small fixed decrements minimize the risk of relapse and adrenal insufficiency, and objective monitoring with UPCR, urinalysis, BP, and eGFR makes the taper reproducible and safer.\n\nTherefore, the calculated initial daily prednisone dose is $60$ mg/day.",
            "answer": "$$\\boxed{60}$$"
        }
    ]
}